Cambrex completed an investment project at its facility in Tallinn, Estonia to upgrade its kilogram-scale lab for the manufacture of pharmaceutical intermediates under current good manufacturing practice (CGMP) conditions.   The project includes the installation of a new 160-liter reactor train, which will expand the site’s capabilities to manufacture material for clinical trials and allow early phase projects to be developed further at the site prior to tech transfer and scale up. Build...